International Journal of Clinical Oncology · 2020 · 65 citations · 32 references
MedicineCancer BiologyOncologyMolecular OncologyNeoplasiaSignal TransductionCancer BiomarkersCancer Cell SignalingLung CancerMalignant NeoplasmsOncogenic Signaling PathwaysSignal Transduction In CancerLung AdenocarcinomaPd-1 SignalingPd-l1 BlockadeProgrammed Cell Death Ligand 1 RegulationProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Cell Death Protein 1 RegulationProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 Targeting
32
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15